A3907 clinical trials

An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults with Primary Sclerosing Cholangitis (PSC)

This study is testing a new medicine, A3907, for people with Primary Sclerosing Cholangitis (PSC). Researchers want to see how safe it is and if people can take it without too many problems over 12 weeks.